2013
Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC).
Solomon B, Gettinger S, Riely G, Gadgeel S, Nokihara H, Han J, Hida T, Satouchi M, Baldini E, Siena S, Yamamoto N, Horn L, Tassell V, Polli A, Camidge D. Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 8105-8105. DOI: 10.1200/jco.2013.31.15_suppl.8105.Peer-Reviewed Original ResearchNon-small cell lung cancerMedian PFSPFS ratesSubgroup analysisSuperior efficacyAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerManageable side-effect profilePrior platinum-based regimenStage IIIB/IVCausality adverse eventsMedian treatment durationPlatinum-based regimenSafety of crizotinibIIIB/IVPhase III studySide effect profileCell lung cancerIndependent radiologic reviewPEM patientsPo bidPROFILE 1007Crizotinib treatmentCare chemotherapyData cutoff
2012
IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ)
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Thomas M, Salgia R, Wilner K, Bartlett C, Polli A, Gandara D. IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ). Annals Of Oncology 2012, 23: xi33. DOI: 10.1016/s0923-7534(20)32007-x.Peer-Reviewed Original ResearchObjective response rateMedian TTPPROFILE 1007Response rateLow objective response rateOngoing phase 3 trialsHigher objective response ratePhase 3 trialLarge retrospective analysisSingle-arm studySmall cohort studiesLarge phase 2High response rateAdenocarcinoma NSCLCBetter PFSCrossover patientsMedian PFSProgressive diseaseCohort studyNSCLC cohortRetrospective studyShorter TTPALK statusRetrospective analysisPemetrexedA large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK -positive ( ALK +) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Thomas M, Salgia R, Wilner K, Bartlett C, Polli A, Gandara D. A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK -positive ( ALK +) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). Journal Of Clinical Oncology 2012, 30: 7599-7599. DOI: 10.1200/jco.2012.30.15_suppl.7599.Peer-Reviewed Original ResearchNon-small cell lung cancerObjective response ratePROFILE 1007Median TTPAdenocarcinoma non-small cell lung cancerALK-positive non-small cell lung cancerResponse rateLow objective response rateOngoing phase 3 trialsHigher objective response ratePhase 3 trialSingle-arm studyLarge retrospective analysisCell lung cancerSmall cohort studiesLarge phase 2High response rateBetter PFSMedian PFSNSCLC cohortProgressive diseaseCohort studyRetrospective studyShorter TTPALK status